MedPath

Prospective comparison of Luseogliflozin and alpha-glucosidase inhibitor on the management of diabetic patients with chronic heart failure and preserved left-ventricular ejection fractio

Not Applicable
Conditions
heart failure
Registration Number
JPRN-UMIN000018395
Lead Sponsor
Cardiovascular Medicine Okayama University Graduate School of. Medicine, Dentistry and Pharmaceutical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
190
Inclusion Criteria

Not provided

Exclusion Criteria

1) BNP <35 pg/ml 2) Patients receiving alpha-glucosidase inhibitors, SGLT2 inhibitors, glinides, high-dose sulfonylurea 3) Patients with renal insufficiency (eGFR< 30 ml/min/1.73m2) 4) LVEF<45% 5) Patients with history of severe ketoacidosis, diabetic coma within six months 6) Patients with serious infection and severe trauma, and perioperative patients 7) Type 1 diabetes mellitus 8) Poorly controlled type2 diabetic patients (HbA1c > 9.0%) 9) Uncontrolled hypertensive patients (systolic blood pressure >160mmHg) 10) Patients with history of stroke, myocardial infarction and severe cardiovascular disease with hospitalization within six months 11) Pregnant women and breast-feeding women 12) Patients with allergy for test drugs 13) Patients who is not suitable to this study due to medical reasons

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in BNP at 12 weeks
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath